Week 8: (−4.7, −3.9 vs (−2.8, −3.1) −2.2 (−2.7, −1.6), −1.8 −0.8) p=0.005* Authors’ conclusion: oral estradiol and venlafaxine are both effective treatments for vasomotor symptoms in midlife women. While “Low-dose efficacy of low-dose estradiol may be slightly superior to that of venlafaxine, the difference is small in magnitude and of uncertain clinical relevance.” Reed et al (2014)3, pharmacologic interventions (estradiol) MsFLASH 03 - Self-reported Oral estradiol 0.5 Placebo Vulvovaginal FSFI - Mean 95% CI (1) Yes** Sexual Function in sexual function mg/day or symptoms and (2) Yes** Women on among venlafaxine 75 sexual function Estradiol vs (3) Yes** Estradiol or depressed midlife mg/day for 8 (used the FSFI (4) Yes** Placebo Venlafaxine for women with weeks and sexually (5) Yes** Hot bothersome hot related personal Baseline: -0.1 (-2.5, EB risk of bias: Flushes: A flushes distress) 2.3) Low Randomized Controlled Week 4: 0.2 (-2.0, 2.3) N = 335 Mean age = Week 8: 1.3 (-0.9, 54.6 years 3.5) Duration = 8 p=0.34 Follow-up = at 8 or 12 weeks Venlafaxine vs Placebo Baseline: -0.5 (-3.3, 2.4) Week 4: 0.8 (-1.1, 2.7)
Week 8: −3.9 (−4.7, −3.1) vs −2.2 (−2.8, −1.6), −1.8 (−2.7, −0.8) p=0.005* Authors’ conclusion: “Low-dose oral estradiol and venlafaxine are both effective treatments for vasomotor symptoms in midlife women. While efficacy of low-dose estradiol may be slightly superior to that of venlafaxine, the difference is small in magnitude and of uncertain clinical relevance.” Reed et al (2014)3, pharmacologic interventions (estradiol) MsFLASH 03 - Sexual Function in Women on Estradiol or Venlafaxine for Hot Flushes: A Randomized Controlled N = 335 Mean age = 54.6 years Duration = 8 Follow-up = at 8 or 12 weeks Self-reported sexual function among midlife women with bothersome hot flushes Oral estradiol 0.5 mg/day or venlafaxine 75 mg/day for 8 weeks Placebo Vulvovaginal symptoms and sexual function (used the FSFI and sexually related personal distress) FSFI - Mean 95% CI Estradiol vs Placebo Baseline: -0.1 (-2.5, 2.3) Week 4: 0.2 (-2.0, 2.3) Week 8: 1.3 (-0.9, 3.5) p=0.34 Venlafaxine vs Placebo Baseline: -0.5 (-3.3, 2.4) Week 4: 0.8 (-1.1, 2.7) (1) Yes** (2) Yes** (3) Yes** (4) Yes** (5) Yes** EB risk of bias: Low depressed